How certain DNA repair genes affect radiation therapy in prostate cancer
Official title: Synergistic DNA repair genes and sensitivity to radiation therapy in prostate cancer
Funded at University of North Carolina Charlotte · NIH-10291608 · Data updated 2026-11-12
This study is looking at how a gene called FAM35A affects how prostate cancer cells react to radiation therapy, especially in cases where the cancer doesn't respond to regular treatments, with the goal of finding better ways to help patients with advanced prostate cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2025 |
| Funding year | 2021 |
| Award (this year) | $446,505 |
| NIH project number | 1R15CA263784-01 |
| Project ID | NIH-10291608 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic prostate cancer or metastatic castration-resistant prostate cancer who are undergoing or considering radiation therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those not receiving radiation therapy may not benefit from this research.
What this research studies
This research investigates the role of a specific DNA repair gene, FAM35A, in how prostate cancer cells respond to radiation therapy. It aims to understand the mechanisms by which FAM35A influences treatment resistance and sensitivity in prostate cancer, particularly in cases that have become resistant to standard therapies. The study will utilize biochemical and cell biology techniques to explore how FAM35A interacts with other proteins involved in DNA repair, potentially leading to improved treatment strategies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation therapies for prostate cancer patients, particularly those with treatment-resistant forms of the disease.
How similar studies have gone: Previous research has shown promising results in understanding DNA repair mechanisms in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of North Carolina Charlotte
Charlotte, United States Active
Researchers
- Principal investigator: Tomida, Junya — University of North Carolina Charlotte
- Study coordinator: Tomida, Junya
Related research
Other NIH-funded projects on the same topics.
-
Embedding symptom support in radiation therapy for prostate cancer
A multi-site study tests whether delivering mindfulness-based symptom support right inside radiation therapy is feasible and acceptable for men with prostate cancer.
-
Advanced MRI to Track Prostate Cancer Treatment
This research explores a new type of MRI scan to see how prostate cancer responds to radiation therapy.
-
New MRI techniques to monitor prostate cancer treatment response
This study is looking at a new type of MRI that uses a special substance to help doctors see how prostate cancer patients are doing after radiation therapy, aiming to give a clearer picture of how the cancer is responding and to spot any remaining or worsening disease.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.